

**UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF OHIO  
EASTERN DIVISION**

IN RE SUBOXONE	)	Case No. 1:24-md-03092
(BUPRENORPHINE/NALOXONE)	)	
FILM PRODUCTS LIABILITY	)	MDL No. 3092
LITIGATION	)	
	)	Judge J. Philip Calabrese
This Document Applies to All Cases	)	
	)	

**MINUTES AND ORDER**

On February 25, 2026, following a working session among counsel, the Court held a status conference in-person on the record.

The following attended on behalf of Plaintiffs: Ashlie Case Sletvold, Erin Copeland, Trent Miracle, and Alyson Beridon.

The following attended on behalf of Defendants Indivior, Inc., Indivior Solutions, Inc., and Aquestive Therapeutics, Inc.: Randall Christian, Mary Pawelek, Jason Lundry, and Patrick DeLaune.

The following attended remotely: Denise Dickerson, Tammy Yonker, Elizabeth Carroll, Roy BenDavid, Alyssa Reinhardt, Kenia Fuentes, Sarah Frank, Gleen Kohles Jr., Asim Badaruzzaman, Luis Escobar, Jessica Wieczorkiewicz, Robin Matney, Bradley East, Deborah Schmitt, Stan Gipe, Kathryn Avila, Ashley Windsor, Shannon McFarland, Meghan P. Connolly, George Senteno, Client James Casperson, Michelle Rodriguez, Laura Smith, Sara J. Watkins, Madeline Wise, Davis Cooper, Joyce Chambers Reichard, Matt Dolman, Carolyn Riley, Kristine Kraft, Stephanie Bovee, Paola Mendoza, Whitney Mennes, Michele Rossi, Dawn Campbell, Edwin

Guyandi, James Seigel, Gerardo Guerra, Joyce Reichard, Linsey Berg, Wesley Elmer, Wesley Guillory, Pamela Corneaux, Denise Perkins, Alex Slepica, Tatum Tipton, Ashlyn Diorio, Layne Hilton, Kenneth Cross, Anthony Russo, Andres Marquez, Jessi Munchak, Cobi Washington, Mark Chavez, Mary Edwards, Linda Wooten, Lisa Gorshe, Maham Khalid, Jessi Muchnick, Becky Dolman, Hope Williams, Audrey Estep, Rachel Archambeau, Nicole Vandewalker, Geoff Teza, Robert Jenkins, Jon Drago, Humaira Safdar, James Wiggin, Meredith Felde, Madeleine Abram, Laura Smith Hatch, Kyle James, Sladjana Gavrilovic, Holly Nighbert, Javon Thompson, Bonnie Rickert, Loren Ngo Kimbell, Sadia Malik, Matthew Sicheri, Jasmin Lopez David Chasen, Victor Alves, Reza Keshavarz, and Matthew Haynes.

On the record, the Court and counsel addressed the items on the agenda (ECF No. 607) with particular attention to the following:

**1. Third-Party Discovery**

On February 25, 2026, the Court also held a show-cause hearing on the record. The Court will enter a separate Order regarding non-compliant providers who failed to appear. Previously, the Court cancelled the hearing on the PLC's motion for contempt.

Defendants advised the Court that certain providers did not receive the Order to Show Cause. And Plaintiffs advised the Court that all Entities subject to their motion for a show cause order (ECF No. 629) are now in compliance. Accordingly, those providers are no longer subject to the Second Amended Show Cause Order (ECF No. 632).

Additionally, the Court discussed Defendants' various motions for an order to show cause as to certain Entities that have failed to comply with requests for medical, dental, and/or pharmacy records by counsel in this litigation that were submitted in compliance with Case Management Order No. 13. (ECF No. 633; ECF No. 638.) The Court will issue a separate Order to Show Cause. That Order will include those providers that did not receive notice of the previous Order to Show Cause. (ECF No. 644.) The Court will hold a hearing on this Order on April 22, 2026.

## **2. Discovery**

### **2.a. Core Discovery**

The PLC and Defendants reported that the process for randomly selecting Plaintiffs to be included in the Core Discovery Pool pursuant to Case Management Order No. 15 is complete. (ECF No. 228.) However, counsel reported that since that selection process, two Plaintiffs dismissed their cases. Accordingly, the Core Discovery Pool currently consists of 98 Plaintiffs.

### **2.b. Status of Schedule A**

The Court raised with counsel the process and timeline for closing out Schedule A. The PLC and Defendants agreed to meet and confer about on the issue and update the Court at the next status conference on March 25, 2026.

### **2.c. NDA Production**

Defendants provided an update on the production of the complete new drug application for Suboxone tablets. Defendants reported that volume 144 has been located and is currently in the process of being produced. Volumes 317 to 333 have still not been located. Currently, it is unknown whether these volumes will be located

or are in the possession of the vendor, which continues to tag boxes of documents at its new facility. Therefore, the Court ordered that if the remaining volumes are not located by March 31, 2026, then the Court and the parties will presume that these volumes will not be located and no longer exist.

**2.d. PLC's First Set of Interrogatories**

The PLC flagged an issue related to an interrogatory intended to identify potential custodians, which may require future Court involvement. Counsel outlined their respective positions on the issue. The PLC and Defendants agreed to continue to meet and confer and bring the issue to the Court's attention, if needed.

**2.e. Deposition Scheduling**

The PLC and Defendants reported that they are coordinating on the scheduling of depositions. Counsel agreed to continue to meet and confer on the dates and sequencing of depositions.

**3. Requests to Withdraw from Representation**

The Court discussed with counsel the multiple requests to withdraw from representation that have been filed and/or provided to the Court. The PLC and Defendants agreed that the motions to withdraw should be held in abeyance pending the current processes already in place for discovery or deficiencies. Counsel advised the Court that they believe these processes will likely resolve most or all issues regarding the requests to withdraw. If not, they will advise the Court. Accordingly, the Court agreed to hold the requests to withdraw from representation in abeyance.

#### **4. Case Schedule**

Pursuant to Case Management Order No. 15 (ECF No. 228), the PLC and Defendants will submit a proposed schedule governing the completion of Core, Trial Pool, and Corporate Discovery by March 9, 2026. As part of that schedule, the Court directed the PLC and Defendants to identify the topics for which they anticipate proffering experts and the total number of experts each side expects to use. However, the parties need not identify the specific experts they intend to use.

#### **5. Suggestions of Death**

The Court discussed with the PLC and Defendants the procedure for handling the filing of suggestions of death. Based on these discussions, the Court entered Case Management Order No. 22 (ECF No. 649).

### **VIRTUAL DISCOVERY HEARING**

The Court sets a virtual discovery hearing for March 10, 2026 at 2:00 p.m. Those who wish to listen by phone shall notify the Court's MDL Clerk, Andrew Rivera ([Andrew.Rivera@ohnd.uscourts.gov](mailto:Andrew.Rivera@ohnd.uscourts.gov)), by March 5, 2026.

Counsel shall confer on the agenda in advance and submit the agenda no later than 10:00 a.m. on March 9, 2026.

### **NEXT STATUS CONFERENCE**

The Court sets a virtual status conference for March 25, 2026 at 9:30 a.m. Those who wish to listen by phone shall notify the Court's MDL Clerk, Andrew Rivera ([Andrew.Rivera@ohnd.uscourts.gov](mailto:Andrew.Rivera@ohnd.uscourts.gov)), by March 20, 2026.

Counsel shall confer on the agenda in advance and submit the agenda no later than 12:00 p.m. on March 20, 2026.

**SO ORDERED.**

Dated: February 27, 2026

A handwritten signature in black ink, appearing to read "J. Calabrese", written in a cursive style.

---

J. Philip Calabrese  
United States District Judge  
Northern District of Ohio